[Home ] [Archive]   [ فارسی ]  
:: Main :: About us :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
Home::
Journal Information::
Articles archive::
For Authors::
For Reviewers::
Subscription::
News& Events::
Contact us::
Site Facilities::
::
Search in website

Advanced Search
..
Receive site information
Enter your Email in the following box to receive the site news and information.
..
Indexing
                        
..
:: Volume 11, Issue 2 (Summer 2014) ::
Sci J Iran Blood Transfus Organ 2014, 11(2): 116-125 Back to browse issues page
Simvastatin synergistically potentiating the anti-tumoreffects of arsenic trioxide on human promyelocyticleukemia (NB-4) cells
S. Ghanizadeh-Vesali , S. Shirali , Farhad Zaker , S. Mohammadi , J. Aryanpour , S.A. Yazdanparast
Abstract:   (8230 Views)

  Abstract

 Background and Objectives

 The efficacy of arsenic trioxide (ATO), as a poisonous drug, in the treatment of acute promyelocytic leukemia (APL) is widely accepted. Due to adverse effects associated with high-dose ATO, the combination therapy is a rational therapeutic strategy to enhance the effectiveness of ATO. In this regard, we used simvastatin (SV), a cholesterol lowering medication, and hypothesized that SV plus ATO would potentiate the efficacy of ATO at lower doses. 

 

 Materials and Methods

 To evaluate the effects of SV and ATO treatment (in isolation or in combination) on transcriptional levels of Bax and Bcl-2, apoptosis, growth kinetic, and metabolic activity of NB-4 cells, we employed RQ-PCR, flowcytometry, trypan blue dye exclusion, and MTT assays, respectively. The data were analyzed using SPSS 21, student’s t-test and one-way ANOVA tests.

 

 Results

 Both SV and ATO considerably hindered the metabolic activity of NB-4 cells in a concentration-dependent manner. In addition, the co-treatment with them exerted an indicative decline in viability, and a significant augmentation in apoptotic population and in the ratio of Bax to Bcl-2 mRNA level. 

 

 Conclusions

 Our results have demonstrated that ATO and SV cooperate synergistically to induce cell death and to inhibit the proliferation rate of NB-4 cells. Furthermore, our results suggest that the combination treatment increased the programmed cell death rate probably through enhancing the intrinsic mitochondrial apoptotic pathway. On aggregate and in view of these data, SV showed the potency for attenuating the effective dose of ATO.

 

   

 

Keywords: Key words: Acute Promyelocytic Leukemia, arsenic trioxide, Simvastatin, Apoptosis
Full-Text [PDF 561 kb]   (1659 Downloads) |   |   Full-Text (HTML)  (2117 Views)  
Type of Study: Research | Subject: Hematology
Published: 2014/06/22
Send email to the article author

Add your comments about this article
Your username or Email:

CAPTCHA


XML   Persian Abstract   Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Ghanizadeh-Vesali S, Shirali S, Zaker F, Mohammadi S, Aryanpour J, Yazdanparast S. Simvastatin synergistically potentiating the anti-tumoreffects of arsenic trioxide on human promyelocyticleukemia (NB-4) cells. Sci J Iran Blood Transfus Organ 2014; 11 (2) :116-125
URL: http://bloodjournal.ir/article-1-732-en.html


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 11, Issue 2 (Summer 2014) Back to browse issues page
فصلنامه پژوهشی خون Scientific Journal of Iran Blood Transfus Organ
The Scientific Journal of Iranian Blood Transfusion Organization - Copyright 2006 by IBTO
Persian site map - English site map - Created in 0.05 seconds with 39 queries by YEKTAWEB 4645